[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"statin-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:statin-therapy":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100568659","ursodeoxycholic-acid-attenuates-statin-induced-impaired-glucose-tolerance-100568659",false,"NCT06684106","Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance","Ursodeoxycholic Acid Attenuates Statin-Induced Impaired Glucose Tolerance: A Randomized Controlled Clinical Trial","URSTAR","Inclusion Criteria:\n\n* Age 18-75 years old.\n* LDL-C≥3.4mmol\u002Fl (130 mg\u002FdL).\n* Glycosylated hemoglobin ≤ 6.0% (42 mmol\u002Fmol).\n* Voluntarily sign informed consent.\n\nExclusion Criteria:\n\n* Previous diagnosis of diabetes or prediabetes.\n* Past or current use of hypoglycemic drugs.\n* Oral administration of statin lipid-lowering drugs within three months before enrollment.\n* Combined oral drug quantity ≥3.\n* History of ASCVD (previous myocardial infarction, ACS, stroke or TIA within 1 year, symptomatic peripheral vascular disease).\n* Active liver disease (defined as elevation of alanine aminotransferase (ALT), aspartate aminotransferase (AST) \\>2 × upper limit of normal (ULN) from any existing known liver infectious, neoplastic, or metabolic pathologic cause or unknown cause at the time of screening), Severe hepatic insufficiency and biliary obstruction.\n* Difficult to control hypertension: defined as systolic blood pressure ≥180mmHg or diastolic blood pressure ≥110mmHg despite antihypertensive therapy prior to randomization.\n* Estimated glomerular filtration rate (eGFR) ≤ 30 mL\u002Fmin\u002F1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) method\n* New York Heart Association (NYHA) Class IV heart failure or a known left ventricular ejection fraction \\\u003C 25%\n* A clinically significant and drug- or ablation-resistant arrhythmia within 3 months prior to randomization\n* An acute or severe systemic infection, or any of the following diseases: hematological disorders, autoimmune disorders, malignant tumors, psychiatric patients, or other serious or unstable conditions that could impact study health status\n* Scheduled for surgery within 6 months\n* Pregnant, breastfeeding, or trying to become pregnant during the study or within 6 months of study completion\n* Subjects with alcohol or other drug addiction\n* Secondary hypercholesterolemia, such as hypothyroidism or nephrotic syndrome\n* A history of allergic reaction to any study drug or its excipients or similar chemical classes of drugs\n* A family history of homozygous familial hypercholesterolemia\n* Participants currently enrolled in another clinical trial, or who cannot adhere to 6-month follow-up\n* Any condition that the investigator considers unsuitable for participation.",true,"ALL","18 Years","75 Years",{"count":22,"type":23},128,"ESTIMATED","INTERVENTIONAL",[26],"NA","The purpose of this clinical trial is to understand whether the drug Ursodeoxycholic acid (UDCA) can prevent glucose intolerance in participants with hyperlipidemia who are taking statins. It will also assess the safety of UDCA. The primary questions it aims to answer are:\n\n* Will UDCA reduce the incidence of glucose intolerance in participants taking oral statins?\n* Will the use of UDCA decrease other adverse events in patients taking oral statins?\n\nParticipants will:\n\n* Take Atorvastatin combined with UDCA or a placebo daily for 6 months\n* Have follow-up visits on day 40, day 110, and day 180 Have their examination indicators recorded.",[29,30,31,32],"Hyperlipidemia","Ursodeoxycholic Acid","Statin Therapy","Glucose Intolerance","RECRUITING","2026-06-26",{"date":36,"type":37},"2026-06-30","ACTUAL",{"date":39,"type":37},"2024-11-25",{"date":41,"type":23},"2027-06-01",{"name":43,"class":44},"First Affiliated Hospital Xi'an Jiaotong University","OTHER",2,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":18,"minAge":53,"maxAge":20,"enrollmentInfo":54,"targetDuration":4,"studyType":24,"phases":56,"briefSummary":57,"conditions":58,"keywords":67,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100562453","changes-in-plaque-characteristics-after-short-term-statin-therapy-as-assessed-with-coronary-ct-100562453","NCT06603363","Changes in Plaque Characteristics After Short-term Statin Therapy as Assessed With Coronary CT","INTENSE","Inclusion Criteria:\n\n* patients referred for coronary computed tomography angiography (CTA)\n* females aged 45-75 years and males aged 40-75 years\n* presence of at least mild coronary atherosclerosis (luminal stenosis \\>25%, with at least one partially calcified or non-calcified plaque)\n* statin-naive patients\n* ability to understand and provide written informed consent\n* FFR-CT value ≥0.75, indicating the absence of hemodynamically significant stenosis\n\nExclusion Criteria:\n\n* contraindications to coronary CTA\n* current or prior treatment with statins or other lipid-lowering agents (e.g., ezetimibe)\n* age below 45 years in females or below 40 years in males\n* age above 75 years in both sexes\n* pregnancy or breastfeeding\n* type 1 or type 2 diabetes mellitus\n* history of coronary stent implantation or coronary artery bypass grafting\n* history of myocardial infarction\n* ≥70% luminal stenosis in the proximal left anterior descending artery (LAD), or ≥50% stenosis in the left main (LM) coronary artery\n* FFR-CT value \\\u003C0.75 in any coronary artery\n* elevated serum alanine aminotransferase (ALT) levels (\\>3× the upper limit of normal)\n* elevated serum creatine kinase (CK) levels (\\>3× the upper limit of normal)\n* LDL cholesterol level \\>5 mmol\u002FL\n* renal failure or significantly impaired renal function (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m²)\n* ongoing oncological treatment\n* active liver disease\n* known hypersensitivity to any excipients of the investigational product\n* concomitant treatment with the combination of sofosbuvir\u002Fvelpatasvir\u002Fvoxilaprevir\n* concomitant treatment with cyclosporine\n* women of childbearing potential not using adequate contraception\n* presence of myopathy","45 Years",{"count":55,"type":23},140,[26],"INTENSE Trial is a prospective, double-blind, randomized, placebo-controlled, single-center study with two arms (40 mg intensified statin therapy vs matching placebo for rosuvastatin) among statin-naive patients referred to coronary CT angiography due to stable chest pain, followed for 24 months by using a photon-counting detector CT (PCD-CT).\n\nINTENSE Trial aims 1) to assess the effect of short-term intensified statin therapy on coronary anatomy and physiology using PCD-CT and 2) to determine the impact of short-term, intensified statin therapy on coronary plaque morphology and hemodynamics to identify statin responder and non-responder patients in addition to testing the hypothesis of \"plaque memory\" after the 24-month follow-up period.",[59,60,61,31,62,63,64,65,66,29],"Coronary Artery Disease","Atherosclerotic Plaque","Coronary Computed Tomography Angiography","Multidetector Computed Tomography","Heart Diseases","Cardiovascular Diseases","Arteriosclerosis","Vascular Diseases",[68,69,70,71,72,73,74,75],"coronary artery disease","stable chest pain","intermediate pretest probability","explanatory randomised controlled trial","coronary computed tomography angiography","photon-counting detector CT","atherosclerotic plaque","statin therapy","2026-05-08",{"date":78,"type":37},"2026-05-13",{"date":80,"type":37},"2025-05-28",{"date":82,"type":23},"2028-12-15",{"name":84,"class":44},"Prof. Maurovich-Horvat Pál",1,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":18,"minAge":93,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":24,"phases":96,"briefSummary":98,"conditions":99,"keywords":102,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":85},"100577952","phase-4-desifor-expand-mhif-100577952","NCT06804980","DESIFOR-EXPAND (MHIF)","The DEterminig Statin Intolerance for Rosuvastatin Trial","Inclusion Criteria:\n\n* Adult patients (≥ 21 years old) with a prior history of statin intolerance. Statin intolerance is defined by discontinuation of at least 2 different statin medications due to possible side effects. Patients can participate in the trial while on other lipid-lowering agents, such as ezetimibe and PSCK9 inhibitors, as long as the patient has been on the other lipid lowering therapy and tolerating it well for at least 1 month. For individuals with established ASCVD or multiple ASCVD risk factors, initiation of other lipid lowering therapy prior to participation in DESIFOR is encouraged.\n* 2\\. At least 30 days since discontinued use of a statin\n\nExclusion Criteria:\n\n* Women who are pregnant, nursing or attempting to become pregnant\n* Individuals who experienced severe reactions in the past, including rhabdomyolysis, severe myositis, anaphylaxis\n* Individuals who are not otherwise clinically indicated to take rosuvastatin 20 mg","21 Years",{"count":95,"type":23},100,[97],"PHASE4","The DESIFOR pilot study was conducted to determine the feasibility of utilizing an n-of-1 trial to facilitate tolerance of unblinded rosuvastatin in patients with prior statin intolerance",[31,100,101],"Statin Adverse Reaction","Statin",[103,104,105,106],"Statin Intolerance","lipid-lowering medication","LDL","LDL Cholesterol","2025-01-28",{"date":109,"type":37},"2025-02-03",{"date":111,"type":23},"2025-02-01",{"date":113,"type":23},"2026-12-31",{"name":115,"class":44},"Minneapolis Heart Institute Foundation"]